Compare Remitly Global Inc (RELY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Remitly Global Inc vs GeneDx Holdings Corp — how do they compare? Remitly Global Inc trades at $23.5 (market cap $4.98B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Remitly Global Inc is far larger — about 2.5× GeneDx Holdings Corp's market cap, and Remitly Global Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Remitly Global Inc for 53 Days and GeneDx Holdings Corp for 19 Days on average.
| RELY | WGS | |
|---|---|---|
Market Cap | $4.98B | $2.02B |
Volume | 3,501,150 | 734,640 |
Sector | Technology | Health |
52-Week High | $26.92 | $167.51 |
52-Week Low | $12.20 | $34.51 |
Typical Hold Time | 53 Days | 19 Days |
Enterprise Value | $4.34B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELY trades at $22.93, down 1.16% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. Revenue has grown from $654M in 2022 to $1.64B in 2025, with net income turning positive at $67.93M. The company recently announced a partnership with Etsy and reported Q2 2026 revenue growth of 20% to $495M, with active customers surpassing 10 million.
The outlook is positive, supported by robust earnings beats, expanding margins, and a consensus analyst price target of $30.50 implying significant upside. Key risks include reliance on continued customer growth, competitive pressures in digital payments, and market volatility. Institutional ownership trends and insider sales warrant monitoring.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
